Stock Events

Stock Events

Neuren Pharmaceuticals 

$8.83
46
+$0.6+7.36% Tuesday 17:43

Statistics

Day High
8.83
Day Low
8.83
52W High
14.8
52W Low
6.6
Volume
-
Avg. Volume
-
Mkt Cap
1.12B
P/E Ratio
51.38
Dividend Yield
-
Dividend
-

Upcoming

Earnings

25FebExpected
Q2 2023
Q3 2023
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
0.01
0.35
0.69
1.03
Expected EPS
0.012652576059780317
Actual EPS
0.11096777818355477

Financials

48.23%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
91.6MRevenue
44.18MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NURPF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.71B
Acadia Pharmaceuticals targets central nervous system disorders, including rare diseases, similar to Neuren's therapeutic areas.
Biogen
BIIB
Mkt Cap25.38B
Biogen focuses on neurodegenerative diseases, multiple sclerosis, and spinal muscular atrophy, competing in the neurological space with Neuren.
PTC Therapeutics
PTCT
Mkt Cap5.83B
PTC Therapeutics works on rare disorders, including neurological diseases, making it a direct competitor to Neuren.
Ionis Pharmaceuticals
IONS
Mkt Cap12.42B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery for neurological diseases, competing with Neuren's focus.
Alnylam Pharmaceuticals
ALNY
Mkt Cap42.72B
Alnylam Pharmaceuticals develops RNAi therapeutics for neurological disorders, directly competing with Neuren's research focus.
Anavex Life Sciences
AVXL
Mkt Cap273.38M
Anavex Life Sciences focuses on neurodegenerative and neurological diseases, including Rett syndrome, a key area for Neuren.
CRISPR Therapeutics
CRSP
Mkt Cap4.92B
CRISPR Therapeutics is engaged in gene editing for various diseases, including potential treatments for neurological disorders, posing indirect competition to Neuren.

About

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
Show more...
CEO
Mr. Jonathan Charles Pilcher A.C.A., B.Sc., BSc (Hons), F.C.A.
Employees
8
Country
Other
ISIN
NZNEUE0001S8

Listings

STU
DE
NK9.STU
F
DE
NK9.F
OTC Link
US
NURPF
AU
AU
NEU.AU

0 Comments

Share your thoughts

FAQ

What is Neuren Pharmaceuticals stock price today?▼
The current price of NURPF is $8.83 USD — it has increased by +7.36% in the past 24 hours. Watch Neuren Pharmaceuticals stock price performance more closely on the chart.
What is Neuren Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Neuren Pharmaceuticals stocks are traded under the ticker NURPF.
Is Neuren Pharmaceuticals stock price growing?▼
NURPF stock has risen by +7.36% compared to the previous week, the month change is a +7.36% rise, over the last year Neuren Pharmaceuticals has showed a +26.07% increase.
What is Neuren Pharmaceuticals market cap?▼
Today Neuren Pharmaceuticals has the market capitalization of 1.12B
When is the next Neuren Pharmaceuticals earnings date?▼
Neuren Pharmaceuticals is going to release the next earnings report on August 25, 2026.
What were Neuren Pharmaceuticals earnings last quarter?▼
NURPF earnings for the last quarter are 0.08 USD per share, whereas the estimation was 0.01 USD resulting in a +777.04% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Neuren Pharmaceuticals revenue for the last year?▼
Neuren Pharmaceuticals revenue for the last year amounts to 91.6M USD.
What is Neuren Pharmaceuticals net income for the last year?▼
NURPF net income for the last year is 44.18M USD.
How many employees does Neuren Pharmaceuticals have?▼
As of April 19, 2026, the company has 8 employees.
In which sector is Neuren Pharmaceuticals located?▼
Neuren Pharmaceuticals operates in the Health & Wellness sector.
When did Neuren Pharmaceuticals complete a stock split?▼
The last stock split for Neuren Pharmaceuticals was on November 21, 2017 with a ratio of 1:20.
Where is Neuren Pharmaceuticals headquartered?▼
Neuren Pharmaceuticals is headquartered in Hawthorn East, Other.